85. W. Krzyzanski, J. J. Perez-Ruixo, J. Harrold. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice. J Pharmacokinet Pharmacodyn (2015). doi: 0.1007/s10928-015-9440-2

84. W. Krzyzanski, Pharmacodynamic models of age-structured cell populations. J Pharmacokinet Pharmacodyn 42:573–589 (2015). doi: 10.1007/s10928-015-9446-9

83. X. Woot de Trixhe, W. Krzyzanski, F. De Ridder, A. Vermeulen, vRNA structured population model for Hepatitis C Virus dynamics. J. Theor. Biol. (2015). doi:10.1016/j.jtbi.2015.04.017

82. I Singh, E. E. Nagiec, J. M. Thompson, W. Krzyzanski, P. Singh, A systems pharmacology model of erythropoiesis in mice induced by small molecule inhibitor of prolyl hydroxylase enzymes. CPT Pharmacometrics Syst. Pharmacol. 4: e12 (2015).doi:10.1002/psp4.12

81. A. P. Singh, W. Krzyzanski, S. W. Martin, G. Weber, A. Betts, A. Ahmad, A. Abraham, A. Zutshi, J. Lin, P. Singh, Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition. AAPS J. (2014). doi: 10.1208/s12248-014-9690-8

80. G. Mo, F. Gibbons, P. Schroeder, W. Krzyzanski, Lifespan based pharmacokinetic-pharmacodynamic model of tumor growth inhibition by anticancer therapeutics. PLoS ONE 9(10): e109747 (2014). doi:10.1371/journal.pone.0109747

79. G. Koch, W. Krzyzanski, J. J. Perez-Ruixo, J. Schropp, Modeling of delays in PKPD: classical approaches and a tutorial for delay differential equations. J. Pharmacokin. Pharmacodyn. 41:291–318 (2014). doi 10.1007/s10928-014-9368-y

78. P. Wiczling W. Krzyzanski W, N. Zychlińska, K. Lewandowski, R. Kaliszan. The quantification of reticulocyte maturation and neocytolysis in normal and erythropoietin stimulated rats. Biopharm. Drug Dispos. 35:330-340 (2014). doi: 10.1002/bdd.1902.

77. M. Elmeliegy, P. Lowe, W. Krzyzanski, Simplification of complex physiologically-based pharmacokinetic models of monoclonal antibodies. AAPS J 16:810-42 (2014). doi: 10.1208/s12248-014-9591-x.

76. Y. Zhang, I. Singh, W. Krzyzanski, Dynamics of erythropoietic markers in response to hypoxia in rats. J Blood Disorders Transf 5:197 (2014).. doi: 10.4172/2155-9864.1000197

Blood Disorders &

75. W. Krzyzanski, M. E. Brier, T. M. Creed, A. E. Gaweda, Reticulocyte-based estimation of red blood cell lifespan. Exp. Hematol. 41:817-822 (2013). doi: 10.1016/j.exphem.2013.05.001

74. R. J. Bauer, G. Mo, W. Krzyzanski, Solving delay differential equations in S-ADAPT by methods of steps. Computer Methods and Programs in Biomedicine 111:715-734 (2013).doi: 10.1016/j.cmpb.2013.05.026

73. X. Yan, W. Krzyzanski, Quantitative assessment of minimal effective concentration of erythropoiesis-stimilating agents. CPT: Pharmacometrics & Systems Pharmacology 2: e62 (2013); doi:10.1038/psp.2013.39

72. S. Doshi, W. Krzyzanski, S. Yue, S. Elliot, A. Chow, J.J. Perez-Ruixo, Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents Clin. Pharmacokinet. 52:1063-1083 (2013) doi: 10.1007/s40262-013-0098-x

71. W. Krzyzanski, Systems pharmacology models for guiding drug design. CPT: Pharmacometrics & Systems Pharmacology 2: e39 (2013) ; doi:10.1038/psp.2013.15

70. W. Krzyzanski, L. Sutjandra, J. J. Perez-Ruixo, B. Sloey, A. T. Chow, Y-M. Wang, Pharmacokinetic and pharmacodynamic modeling of romiplostim in animals, Pharm. Res. 30: 655-669 (2013).

69. X. Yan, S. Ait-Oudhia, W.Krzyzanski, Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness. Pharm. Res. 30:1026-1036 (2013).

68. X.Yan, Y. Chen, W. Krzyzanski, Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor. J. Pharmacokin. Pharmacodyn. 39:543–560 (2012).

67. X.Yan, W. Krzyzanski, Dose correction for the Michaelis-Menten approximation of the target-mediated drug disposition model. J. Pharmacokin. Pharmacodyn. 39:141–146 (2012).

66. W. Krzyzanski and J. J. Perez Ruixo, Lifespan based indirect response models. J. Pharmacokin. Pharmacodyn. 39:109–123 (2012).

65. X. Yan, P. J. Lowe, M. Fink, A. Berghout, S. Balser, W. Krzyzanski, Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human epoetin alfa and the biosimilar HX575. J. Clin. Pharmacol. 52:1624-1644 (2012).

64. M. A. Felmlee, W. Krzyzanski, B. L. Morse, M. E. Morris, Use of a local sensitivity analysis to inform study design based on a mechanistic toxicokinetic model for γ-hydroxybutyric acid. AAPS J. (2011).

63. R. Achuthanandam, D. Makropoulos, L. Johns, A. Volk, K. Brosnan, J. Lu, W. Krzyzanski, P. J. Bugelski, Pharmacodynamics of CNTO 530 and darbepoetin-α in human TNF-a transgenic mice, a murine model of anemia of chronic disease. Pharmacology and Pharmacy 2:17-30 (2011).

62. S. Ait-Oudhia, A. Vermeulen, W. Krzyzanski, Non-linear mixed effects modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharm. Drug Dispos. 32:1-15 (2011).

61. W. Krzyzanski, Interpretation of transit compartment pharmacodynamic models as lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 38:179-204 (2011).

60. Y-M. Wang, W. Krzyzanski, S. Doshi, J. J. Xiao, J. J. Perez Ruixo, A. T. Chow, Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects. AAPS J. 12:729-740 (2010).

59. J.J. Xiao, W. Krzyzanski, Y-M. Wang, H. Li, M. J. Rose, M. Ma, Y. Wu, B. Hinkle, J. J. Perez-Ruixo, Pharmacokinetics of anti-hepcidin monoclonal antibody Ab 12B9m and hepcidin in cynomolgus monkeys. AAPS J. 12:646-657 (2010).

58. W. Krzyzanski, P. Wiczling, P. Lowe, E. Pigeolet, M. Fink, A. Berghout, S. Balser, Population modeling of filgrastim PK-PD in healthy adults following intravenous and subcutaneous administrations. J. Clin. Pharmacol. 50:101S-112S (2010). doi:

10.1177/0091270010376966

57. S. Ait-Oudhia, J-M. Scherrmann, W. Krzyzanski, Simultaneous pharmacokinetic/pharmacodynamic modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. J. Pharmacol. Exp. Ther. 334:897–910 (2010).

56. S. Ait-Oudhia, J-M. Scherrmann, W. Krzyzanski, Time-dependent clearance and hematological pharmacodynamics upon erythropoietin multiple dosing in rats. Biopharm. Drug Dispos. 31:298-315 (2010).

55. X. Yan, D. E. Mager, W. Krzyzanski, Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J. Pharmacokinet. Pharmacodyn. 37:25-48 (2010).

54. L. A. Khinkis, W. Krzyzanski, W. J. Jusko, W. R. Greco, D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J. Pharmacokinet. Pharmacodyn. 36:523-539 (2009).

53. P. Wiczling, P. Lowe, E. Pigeolet, F. Ludicke, S. Balser, W. Krzyzanski, Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. Clin. Pharmacokinet. 48:817-826 (2009).

52. J. J. Perez-Ruixo, W. Krzyzanski, E. Bouman-Thio, B. Miller, H. Jang, S. A. Bai, H. Zhou, J. Yohrling, A. Cohen, J. Burggraaf, K. Franson, H. Davis, Pharmacokinetics and pharmacodynamics of the erythropoietin mimetibody construct CNTO 528 in healthy subjects. Clin. Pharmacokinet. 48:601-613 (2009).

51. P. Wiczling, S. Ait-Oudhia, W. Krzyzanski, Flow cytometric analysis of reticulocyte maturation after erythropoietin administration in rats. Cytometry Part A 75A:584-592 (2009).

50. A. Marathe, W. Krzyzanski, D. E. Mager, Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model. J. Pharmacokinet. Pharmacodyn. 36:199-219 (2009).

49. W. Krzyzanski, J. J. Perez-Ruixo, A. Vermeulen, Basic pharmacodynamic models for agents that alter the lifespan distribution of natural cells. J. Pharmacokinet. Pharmacodyn. 35:349-377 (2008).

48. M. Danielewski, K. Holly, W. Krzyzanski, Interdiffusion in r-component (r ³ 2) one dimensional mixture showing constant concentration, Computer Methods in Materials Science 8:31-46 (2008).

47. J. J. Perez-Ruixo, W. Krzyzanski, J. Hing, Pharmacodynamic analysis of recombinant human erythropoietin effect on reticulocyte production rate and age distribution in healthy subjects. Clin. Pharmacokinet. 47:399-415 (2008).

46. S. Woo, W. Krzyzanski, W. J. Jusko, Pharmacodynamic model for chemotherapy induced anemia in rats. Cancer Chemother. Pharmacol. 62:123-133 (2008).

45. S. Woo, W. Krzyzanski, A.-M. Duliege, R. B. Stead, W. J. Jusko, Population pharmacokinetics and pharmacodynamics of peptidic erythropoiesis receptor agonist (ERA) in healthy volunteers. J. Clin. Pharmacol. (2008).

44. P. Wiczling, W. Krzyzanski, Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp. Hematol. 36:119-127 (2008).

43. W. Krzyzanski, E. Wyska, Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn-Schmiedeberg’s Arch. Pharmacol. 377:637-645 (2008).

42. S. Woo, W. Krzyzanski, W. J. Jusko, Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J. Pharmacokinet. Pharmacodyn. 34:849-868 (2007).

41. A. K. Abraham, W. Krzyzanski, D. E. Mager, Partial derivative-based sensitivity analysis of models describing target-mediated drug disposition, AAPS J. 9 Article 20 (2007) (http://www.aapsj.org).

40. P. Wiczling, W. Krzyzanski, Method of determination of the reticulocyte age distribution from flow cytometry count by a structured-population model. Cytometry Part A 71A:460-67 (2007).

39. W. Krzyzanski, J. Oberdoester, R. R. Rabin, Mechanism of ethanol enhancement of apoptosis and caspase activation in serum-deprived PC12 cells. Life Sciences 81:756-764 (2007).

38. R. M. Straubinger, W. Krzyzanski, C. M. Francoforte, J. Qu, Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. Anticancer Res. 27:1237-46 (2007).

37. W. Krzyzanski, J. Bell, Modelling the geometric features and investigating electrical properties of dendrites in a fish thalamic neuron. Math. Med. Biol. 24: 271-286 (2007).

36. W. Krzyzanski, J. J. Perez-Ruixo, An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm. Res. 24:758-771 (2007).

35. A. Hazra, W. Krzyzanski, W.J. Jusko, Mathematical assessment of properties of precursor-dependent indirect pharmacodynamic response models. J. Pharmacokin. Pharmacodyn. 33:683-717 (2006).

34. S. Woo, W. Krzyzanski, W. J. Jusko, Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J. Pharmacol. Exp. Ther. 319:1297-06 (2006).

33. W. Krzyzanski, J. Dmochowski, N. Matsushima, W. J. Jusko, Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models. J. Pharmacokin. Pharmacodyn. 33:635-655 (2006).

32. Z. Yao, W. Krzyzanski, W. J. Jusko, Assessment of basic indirect pharmacodynamic response models with physiological limits. J. Pharmacokin. Pharmacodyn. 33:167-193 (2006).

31. W. Krzyzanski, S. Woo, W. J. Jusko, Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J. Pharmacokin. Pharmacodyn. 33:125-165 (2006).

30. N. M. Jamal, W. Krzyzanski, W. Cheung, C. Y. Lau, and H. A. Messner, Evaluation of epoetin alpha (rHuEPO) and darbepoetin alpha (DARB) on human burst-colony formation (BFU-E) in culture. J. Int. Med. Res. 34:42-51 (2006).

29. J. J. Perez-Ruixo, H. C. Kimko, A. C. Chow, V. Piotrovsky, W. Krzyzanski, and W. J. Jusko, Population cell lifespan models for effects of drugs following indirect mechanism of action. J. Pharmacokin. Pharmacodyn. 32: 767-793 (2005).

28. D. E. Mager and W. Krzyzanski, Quasi-equilibrium pharmcokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res. 22: 1589-96 (2005).

27. W. Krzyzanski, W. J. Jusko, M. C. Wacholtz, N. Minton, W. K. Cheung, Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur. J. Pharm. Sci. 26:295-306 (2005).

26. J. Earp, W. Krzyzanski, A. Chakraborty, M. K. Zamacona, W. J. Jusko, Assassment of drug interactions relevant to pharmcodynamic indirect response models. J. Pharmcokin. Pharmacodyn. 31:345-380 (2004).

25. F. Jin and W. Krzyzanski, Pharmacokinetic model of target-mediated disposition of thombopoietin, AAPS PharmSci 6: Article 9 (2004).

24. E. Wyska, D. E. Mager, W. Krzyzanski, Methods of estimation IC₅₀ and SC₅₀ parameters for indirect response models from single dose data. J. Pharm. Sci. 92: 1438-54 (2003).

23. W. Krzyzanski, J. Bell, R. R. Poznanski, Neuronal integrative analysis of the “dumbbell” model for passive neurons, J. Integr. Neurosci. 1: 217-239 (2002).

22. S. H. Bernstein, W. J. Jusko, W. Krzyzanski, J. Nichol and M. Wetzler, Pharmacodynamic modeling of thrombopoietin, platelet and megakaryocyte dynamics in patients with acute myeloid leukemia undergoing dose intensive chemotherapy, J. Clin. Pharmacol. 42: 501-11 (2002).

21. W. Krzyzanski and W. J. Jusko, Multiple-pool cell lifespan model of hematologic effects of anticancer agents, J. Pharmacokin. Pharmacodyn. 29:311-337 (2002).

20. I. Perlstein, D. Stepansky, W. Krzyzanski, and A. Hofman, A signal transduction pharmacodynamic model of the kinetics of parasympathomimetic activity of low-dose scopolamine and atropine in rats. J. Pharm. Sci. 91: 2500-10 (2002).

19. W. Krzyzanski, An application of a weak solution of the cable equation to the Rall model of a nerve cell, IMA J. Math. Appl. Med. Biol. 18: 377-407 (2001).

18. T. A. Puchalski, W. Krzyzanski, and W. J. Jusko, Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model, J. Clin. Pharmacol. 41: 251-258 (2001).

17. W. Krzyzanski and W. J. Jusko, Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition, J. Pharmacokin. Pharmacodyn. 28: 57-78 (2001).

16. W. Krzyzanski, Asymptotics of the total net direct effect for large drug doses, J. Math. Biol. 41: 477-492 (2000).

15. W. Krzyzanski, A. Chakraborty, and W. J. Jusko, Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models, Chronobiol. Int. 17: 77-94 (2000).

14. M. Danielewski, W. Krzyzanski, and R. Bachorczyk, Generalized Darken’s method; from diffusional structures to nonparabolic diffusion. Solid State Phenomena 72: 141-152 (2000).

13. W. Krzyzanski, R. Ramakrishnan, and W. J. Jusko, Basic models for agents that alter production of natural cells, J. Pharmacokin. Biopharm. 27: 467-489 (1999).

12. W. Krzyzanski and J. Bell, Analysis of a model of membrane potential for a skin mechanoreceptor, Math. Biosci. 158: 1-45 (1999).

11. A. Chakraborty, W. Krzyzanski, and W. J. Jusko, Mathematical modeling of circadian cortisol concentrations in indirect response models, J. Pharmacokin. Biopharm. 27: 23-43 (1999).

10. M. Danielewski, W. Krzyzanski, B. Figura, P. Kita, G. Pecak, The non-reduced solution of the Fisher model, grain boundary diffusion in R³, Metallofiz. Noveishie Tekhnol. 21: 55-60 (1999).

9. W. Krzyzanski and W. J. Jusko, Caution in use of empirical equations for pharmacodynamic indirect response models, J. Pharmacokin. Biopharm. 26: 735-741 (1998).

8. W. Krzyzanski and W. J. Jusko, Characterization of pharmacodynamic recession slopes for direct and indirect response models, J. Pharmacokin. Biopharm. 26: 409-436 (1998).

7. W. Krzyzanski and W. J. Jusko, Mathematical formalism and characteristics of four basic models of indirect pharmacodynamic responses for drug infusions, J. Pharmacokin. Biopharm. 26: 385-408 (1998).

6. W. Krzyzanski and W. J. Jusko, Integrated functions for four basic models of indirect pharmacodynamic response, J. Pharm. Sci. 87: 67-72 (1998).

5. W. Krzyzanski and W. J. Jusko, Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses, J. Pharmacokin. Biopharm. 25: 107-123 (1997).

4. W. Krzyzanski and W. J. Jusko, Application of moment analysis to the sigmoid effect model for drug administered intravenously, Pharm. Res. 14: 949-952 (1997).

3. M. Danielewski and W. Krzyzanski, Momentum and energy in open systems, Phys. Stat. Sol. (a) 145: 351-361 (1994).

2. M. Danielewski, K. Holly, and W. Krzyzanski, Interdiffusion in r-component (r³2) one dimensional mixture showing constant concentration, Polish J. Chem. 68: 2031-47 (1994).

1. W. Krzyzanski, Expansion of the solution of the Neumann problem for the Poisson equation into the Fourier series with respect to eigenfunctions of this problem. Universitatis Iagellonicae Acta Mathematica 30: 199-213 (1993).